Interview 31 Oct 2018 Biotech Investment Strategies: How, When and Where to Invest …CNS — those are the indication areas that will provide the majority of biotech opportunities. But ultimately we are looking at each investment by itself. Sometimes we invest in things… October 31, 2018 - 6 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 10 Sep 2025 Kriya Therapeutics has raised over $1.2 billion, but for what? …when administered as an injection by penetrating the central nervous system (CNS) to reduce the severity and number of pain attacks. While early preclinical data on its geographical atrophy therapy… September 10, 2025 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 27 Feb 2024 Japan’s ten hottest biotech companies in healthcare …model, enabling the generation of peptide libraries for hit finding. PeptiDream’s pipeline is diverse and spans a range of therapeutic areas, including oncology, CNS disorders, and immunology. With over 120… February 27, 2024 - 12 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 19 Jan 2026 Curing ALS? Ten companies developing new treatments in 2026 …CNS delivery capabilities. Eli Lilly has also been particularly active via partnerships with smaller players in the ALS ecosystem. While ALS remains a smaller part of the neurodegenerative sector, it does show momentum, and there are many… January 19, 2026 - 12 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Podcast 12 Apr 2024 Redefining chronic pain treatment …Doloromics is delineating the idea of nociception versus pain itself. Nociception is the central nervous system (CNS) and peripheral nervous system (PNS) processing noxious stimuli. When nociceptors and their pathways… April 12, 2024 - 10 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Nov 2021 Big Pharma Strikes Megadeals In Targeted Protein Degradation …on this as well as oncology targets, several of which are not accessible by PROTACs. “Dunad’s platform is designed to enable the development of orally bioavailable and CNS-accessible monovalent protein degraders – an approach… November 12, 2021 - 5 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
News and Trends 17 Oct 2022 CRISPR/Cas9: Challenges and outlook from an investor’s perspective …viability of CRISPR/Cas9 therapeutics for common conditions is the ability to penetrate the CNS and other tissues such as muscles. This is where novel delivery systems come into play. What… October 17, 2022 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
In Depth 14 Jun 2023 How are biotechs addressing rare chromosome disorders? …spinal canal, GTX-102 works by reactivating the expression of the paternal UBE3A allele in neurons of the central nervous system (CNS). This has been linked to improved neurological symptoms in… June 14, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Expert Advice 15 Mar 2024 Is biotechnology a good career? Here are the pros and cons …expanding, offering ample opportunities for career advancement, as well as being able to apply your skills across different types of companies, e.g. from CNS [central nervous system] to oncology,” said… March 15, 2024 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 8 Jan 2025 Ten drugs to watch in 2025: will these therapies become blockbusters? …giant Lilly several decades ago. Xanomeline, which is a muscarinic agonist that stimulates the muscarinic M1 and M4 receptors in the central nervous system (CNS) by crossing the blood-brain barrier,… January 8, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jun 2023 Minoryx can start phase 3 trial for cerebral adrenoleukodystrophy patients …best-in-class profile for CNS diseases. It has demonstrated brain penetration and a favorable safety profile. It showed robust preclinical proof-of-concept in animal models of multiple diseases by modulating pathways leading… June 8, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 28 Jan 2026 Seven Italian biotechs to know about in 2026 …discovery or optimization. In the last couple of years, Sibylla has looked quieter publicly, but it signed a strategic discovery collaboration with Ono Pharmaceutical in central nervous system (CNS) disorders, although the company did not disclose the… January 28, 2026 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email